Eli Lilly is investing $5.3 billion in a new Indiana plant to increase production of diabetes and weight loss drugs, raising total facility investment to $9...
BaseLaunch, a Basel biotech incubator, gains support from AbbVie, joining Roche, Novo Nordisk, Johnson & Johnson, and CSL Behring. Operated by Basel Area Business & Innovation,...
Until now, in the field of anti-obesity treatments, there was a drug that attracted attention: Ozempic. It is also made by Novo Nordisk and is very...
Novo Nordisk sees substantial growth, reporting a 28% increase in profits to €3.4 billion in Q1 2024, with operating profits up 27% to €4.27 billion. This...
Wegovy stands as Novo Nordisk's big bet. This medicine was what placed the Danish multinational company as the most valuable company in Europe last September, surpassing...
In 2024, Novo Nordisk expects its sales to increase between 18% and 26% at constant exchange rates, while it anticipates operating profit growth at constant exchange...
Novo Nordisk has entered independent research collaboration agreements with Omega Therapeutics and Cellarity to develop innovative therapeutic approaches for cardiometabolic diseases, with each company potentially receiving...
The demand for products indicated against diabetes has increased. Large groups in the sector announced new investment plans to grow in this segment. However, not everything...
Novo Nordisk plans a €2.1 billion investment to strengthen its presence in France's industrial sector, according to French President. The biotech company aims to expand the...
More than half of the population of the countries of the Organization for Economic Cooperation and Development (OECD) was overweight or obese, according to the latest...